June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

CryoLife (CRY) Raised To Strong Buy On Estimate Revisions

Published 06/13/2016, 07:05 AM
Updated 07/09/2023, 06:31 AM
MASI
-
MLAB
-
AORT
-
IRMD
-

On Jun 11, Zacks Investment Research raised CryoLife Inc. (NYSE:CRY) to a Zacks Rank #1 (Strong Buy).

Why the Upgrade?

The upgrade was primarily driven by solid estimate revisions over the last 60 days.

The Zacks Consensus Estimate for full-year 2016 is currently pegged at 23 cents per share, which moved up 14 cents over the time frame, as most of the analysts revised their estimates upward.

Meanwhile, the Zacks Consensus Estimate for full-year 2017 has been revised upward by 36% (9 cents) to 34 cents per share.

CRYOLIFE INC Price and Consensus

CRYOLIFE INC Price and Consensus | CRYOLIFE INC Quote

Key Growth Factors

The estimate revisions were primarily driven by CryoLife’s strong first-quarter 2016 results. Adjusted earnings of a dime in the quarter outpaced the Zacks Consensus Estimate by 8 cents (400.0%).

Adjusted revenues increased 9% from the year-ago quarter to $43 million. This figure included revenues from the On-X acquisition as well as divestitures of HeRo and ProCol. On an adjusted basis, On-X revenues increased 7% year over year to $8.3 million.

Moreover, tissue processing business revenues increased 11%, driven by strong demand for CryoLife’s vascular tissue products. Total BioGlue revenues increased 9% in the quarter.

The ongoing clinical trial for PerClot IDE is a key catalyst for CryoLife. The company is currently in discussion with the FDA to change the trial protocol. CryoLife expects to resume enrolling patients in the trial during the second half of the year.

CryoLife is also continuing its clinical trial in order to gain FDA approval in China for the BioGlue product.

Moreover, the acquisitions of On-X and PhotoFix expand the company’s product portfolio. On the other hand, the divestitures of the HeRo and ProCol products will help the company focus on its core business.

Other Stocks to Consider

One may also consider other favorably ranked stocks like Iradimed Corp (NASDAQ:IRMD) , Masimo Corporation (NASDAQ:MASI) and Mesa Labs Inc (NASDAQ:MLAB) in the same space. All the three stocks sport a Zacks Rank #1 (Strong Buy).



MASIMO CORP (MASI): Free Stock Analysis Report

MESA LABS INC (MLAB): Free Stock Analysis Report

IRADIMED CORP (IRMD): Free Stock Analysis Report

CRYOLIFE INC (CRY): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.